Tirzepatide Dosing Calculator, Protocols, and Dosage Chart

PeptideFox Research Team Perspective

The first thing to understand about tirzepatide is that it is the strongest appetite suppressant in the class. It does not just quiet food noise, it makes eating genuinely hard. That single fact explains most of what it is good at, and the one thing it is not.

It is more than a stronger semaglutide, and the difference is mechanical. Tirzepatide recruits the GLP-1 receptor's shut-off signal the least of any drug here, so it holds its effect longer for each unit of receptor engaged, and it reaches more weight loss while engaging far less GLP-1 receptor than semaglutide does, because the GIP arm carries part of the load. Its GIP arm also quiets the brainstem nausea the GLP-1 arm provokes, which is the only reason a drug with this much appetite effect can be titrated at all.

The part that matters most for anyone who cares about their body and not just the scale is lean mass. Tirzepatide preserves it far better than semaglutide, and it does so across the whole dose range. The reason is the GIP loading. GIP acts directly on fat cells to burn energy as heat and it improves insulin handling, and that combination lets the body shed fat without spending muscle the way a pure appetite-suppression signal does. Semaglutide has none of this. So the fat-to-lean quality of the loss is not a small edge between the two drugs, it is the main one.

That same appetite suppression is why tirzepatide is a poor recomposition tool, which surprises people who assume the strongest drug is the best for everything. Recomposition means building muscle while dropping fat, and building muscle requires eating: protein, training fuel, enough intake to drive adaptation. A drug that makes eating hard works against exactly that. For losing fat while holding muscle, tirzepatide is excellent. For actively recomposing on a full training stimulus, its greatest strength gets in the way.

Where a low dose earns its place is narrower than the hype suggests. It is a clean tool for holding food noise down consistently, and it is a real option for someone who wants stronger appetite control than retatrutide gives, without retatrutide's cardiac and glucagon-driven side effects. That is a specific job, not a general-purpose metabolic base.

Tirzepatide (Mounjaro / Zepbound) Dosing: What the Three Floors Hide

Tirzepatide is the weekly dual-hormone injection sold as Mounjaro for type 2 diabetes and Zepbound for obesity. In the 72-week obesity trial it took average body weight down 20.9% at the top dose, and in the direct comparison against semaglutide it won outright, 20.2% versus 13.7%.¹ ² What separates it from every other approved GLP-1 drug is a second receptor. It carries a strong GIP signal that semaglutide has none of, and that second arm is why it out-loses a pure GLP-1 drug at the population level.⁷ ¹⁷

That 20.9% is one cohort's reading, not a universal number. Those trial subjects averaged about 105 kg at a BMI of 38 and were mostly sedentary; a lighter or leaner body gets more drug per pound and reads several effects differently. Every trial figure on this page is a measurement taken through a particular body, so treat it as a number to translate to yours, not a menu to copy. The phenotype and heart-rate sections below are where that translation happens.

The number most pages get wrong is where the dose starts. Tirzepatide has three different floors, and they answer three different questions. The label starts at 2.5 mg weekly. The lowest dose with long-duration obesity-trial evidence is 5 mg. The lowest dose ever measured for pharmacologic activity in a registered trial is 1 mg, from an early diabetes study.¹ ²¹ Collapsing those into one number is where most dosing advice goes wrong.

The evidence base is two trial programs in one coat. SURMOUNT is the obesity side, where weight is the endpoint. SURPASS is the diabetes side, where blood-sugar control is the endpoint and tirzepatide's distinguishing mechanism (GIP-driven insulin sensitization⁷ ¹³) shows most clearly. The right dose depends on which of those you are, and on the body reading the signal.

Every dose is weekly. What separates the rungs is not cadence but the evidence standing behind each one, read low to high.

How Tirzepatide's Two Signals Work

Tirzepatide is not a stronger copy of your own gut hormones. The body's GLP-1 and GIP fire in short bursts after a meal and clear from the blood within minutes. Tirzepatide holds both signals switched on for a week at a time.⁷ The receptor system is built for brief blips followed by long quiet; the drug gives it a continuous field instead. That single difference, tonic instead of pulsed, is why a weekly injection reaches appetite centers and metabolic tissue that a two-minute meal signal never touches at a meaningful level.

It is also lopsided by design. The public shorthand is "dual GIP/GLP-1 agonist," which reads as a balanced 50/50 drug. It is not. Tirzepatide engages the GIP receptor at close to your own hormone's strength, but hits the GLP-1 receptor about 18 times more weakly than natural GLP-1.⁷ Once you account for how tightly the drug rides on blood protein, the in-body imbalance widens to roughly 20-fold GIP-forward. So the correct one-line description is a GIP-forward drug with a weaker, deliberately reshaped GLP-1 arm, and no working glucagon arm at all.⁷

The chart above is the whole dosing logic in one picture. The GIP line runs far ahead at every dose and reaches roughly half-occupied by 15 mg. The GLP-1 line stays low but never flattens: it is still climbing at the top of the approved range, which is why each higher step keeps changing how the drug feels. The glucagon line sits on the floor the entire way, below 0.3% even at 15 mg. That flat line is the point. It rules out the glucagon-driven liver and heart effects that belong to a triple-receptor drug like retatrutide.⁷

GIPR: the identity receptor

The GIP arm is what makes tirzepatide tirzepatide. At the 2.5 mg starter dose it is already engaging real receptor (about 13% occupied), and by 5 mg it sits near what a large meal produces at its peak, except held there continuously rather than for a few minutes.⁷ This arm carries the insulin-sensitizing effect that shows up in diabetes: across the diabetes program, every dose raised insulin sensitivity while lowering the amount of insulin the body had to make (a sensitization signature¹³), the opposite of a drug that whips the pancreas harder. The GIP arm also runs a brainstem anti-nausea circuit that lets a strong drug carry its gut load with fewer people quitting than raw GLP-1 pressure alone would cost.⁷

GLP-1R: appetite, tolerability, and heart rate

The GLP-1 arm carries appetite suppression, the slowing of stomach emptying, most of the nausea, and the heart-rate signal. Occupancy stays low, but low does not mean weak here. Tirzepatide's GLP-1 signal is reshaped so that each engaged receptor keeps generating its main downstream message longer than a balanced drug would (a cAMP-biased signal with low receptor pull-in⁷). The clearest proof that a single-digit occupancy does real work: in a head-to-head against liraglutide, a full-strength GLP-1 drug that forces far higher occupancy, tirzepatide cut measured food intake and food craving more, not less.¹⁷ The appetite effect is a drop in the drive to eat, not a test of willpower.

GCGR: the negative control

Glucagon is on the chart only to be ruled out. Tirzepatide's glucagon-receptor occupancy stays under 0.3% even at 15 mg.⁷ So its liver-fat reduction, its lipid improvements, and its heart-rate rise do not run through a glucagon arm the way retatrutide's do. They run through weight loss, insulin sensitization, and the GLP-1 arm. When a tirzepatide result points the same direction as a glucagon-drug result, the cause is shared downstream physiology, not a hidden third receptor.

Reading Each Dose on the Ladder

The best dose is the lowest one that keeps the right markers moving with side effects you can live with. For active loss those markers are appetite, weight trend, waist, glucose, blood pressure, and tolerability. For maintenance they shift to weight stability, waist, hunger, strength, and labs.

The 2.5 mg start is not a placebo runway. It is pharmacologically live at the GIP arm; it starts low because the appetite and gut side needs time to adapt before the dose climbs.⁷ At 5 mg both arms are clinically active for the first time, which is why it is the obesity-trial floor. From 7.5 to 10 mg the GLP-1 arm roughly doubles from its 5 mg level and the high-response phenotype starts to emerge: deeper appetite suppression, more visible heart rate, and gut symptoms that can return with each step up. The 12.5 to 15 mg band adds only modestly to the obesity trial's average weight loss but widens its responder tail, and it is where the heart-rate, gut, over-loss, and lean-mass ceilings need the most attention.⁷

Tirzepatide has a roughly 5-day half-life. Blood levels rise across the first several weekly doses and settle near steady state after about four weeks.⁸ That is why the four-week hold matters: the full effect of a dose change is not visible in the first few days.

What Tirzepatide Feels Like, Week to Week

The single most-reported effect of tirzepatide is not on any rate table. Food noise goes quiet — the constant background pull toward food, the mid-afternoon loop about snacks, the running negotiation over every meal. It often drops within a day or two of the first shot, and in the withdrawal trial it was the first thing people noticed on the way up and the first thing to return on the way down, which makes it the felt gauge of whether the drug is working.¹² ²³

Hunger changes shape, not just size

Hunger does not simply shrink; the relationship to food reorganizes, and three things that normally move together come apart. Physical hunger still registers. The wanting — the craving, the anticipation, the reward of eating — drains out. Against a full-strength GLP-1 drug head to head, tirzepatide cut craving and the pull of food that is present more, while leaving willpower and restraint untouched, so the felt experience is "I could eat it, I just don't want it," not white-knuckling.¹⁷ And portions collapse on their own: delayed stomach emptying means a few bites fill you and hold for hours, so you push the plate away half-full without deciding to.⁹

The quiet cuts two ways, and the split is real. For someone whose eating ran on stress, reward, or a constant mental battle, it is enormous relief — people describe eating "freely, without anxiety" and a lift in mood that has nothing to do with the scale.²³ For someone whose meals were a genuine daily pleasure, the same flatness reads as a loss: food stops being interesting, and a minority describe a low-grade numbness around it. The trials lean the first way, with mood scores drifting slightly better rather than worse, so the flatness is a real minority experience the trial instrument does not capture, not a headline effect.

The week-to-week arc

The 2.5 mg start is often underwhelming. It is light on the appetite arm, so some people feel food go quiet in days and others feel almost nothing and wrongly decide it "isn't working." The pattern to expect is the 24-to-72-hour window after each dose increase: drug levels peak a day or two after the shot, and the higher dose re-engages stomach-slowing before the body adapts, so the day after is when nausea, fullness, and the wall land.⁸ The community routine is built around exactly this — inject on a Friday so the worst falls over the weekend, eat a small high-protein meal beforehand, walk after. It eases across the four-week hold. Later, at a steady dose, the effect softens: food noise creeps partway back and appetite returns, which is the felt version of the plateau and the reason people reach for the next rung.¹² Stopping runs the tape backward, and food noise returns first and loudest.¹²

The side effects that dominate the lived complaints

The effects users complain about most are not the ones the rate tables rank first. Nausea leads the tables but concentrates during escalation and fades. Constipation is the sleeper: it runs roughly flat across doses and grinds on, and users describe "industrial constipation" as the thing that nearly made them quit.⁸ ²³ The other signature is sulfur burps, sometimes described as "burping while full of helium" — the eggy, high-pressure reflux of food sitting longer in a slowed stomach.⁹ ²³ Fatigue is under-weighted on the label and sits second only to nausea in patient forums, and much of it is the calorie deficit rather than the molecule.²³ Specific foods turn actively unpleasant, usually fried and fatty food and sometimes coffee or meat, and many people find their desire for alcohol falls off on its own, a standing weekend habit shrinking to a glass or none.²³

The effects that sit outside the trial tables

Two things deserve naming because a user will not find them on the label. Menstrual-cycle changes are among the most-discussed effects in patient communities, with irregular or doubled-up cycles during rapid loss, and the trials never pre-specified them, so they are missing from the adverse-event tables without being missing from users.²³ And the emotional dimension above cuts both ways. Neither is cause for alarm; both are reasons to know what you are looking at.

What to do about it

Protein and resistance training are the levers that decide whether the weight leaves as fat or as muscle, and they matter more in a leaner body with less to spare (the phenotype and lean-mass sections carry the detail). Plan the injection around the day-after window. Watch whether a symptom is adapting or persisting: nausea should ease, while constipation usually needs a magnesium or fiber routine rather than a dose you tough out. And separate the drug from the deficit — the fatigue, the light-headedness, and some of the low mood are the calorie gap talking, and they answer to protein, electrolytes, and sleep before they answer to the dose.

What Different Bodies Do at the Same Dose

The receptor chart does not change by phenotype. What the body does with that same signal changes a great deal. Type 2 diabetes, body weight, sex, baseline fat, and cardiac responsiveness all reshape the output.

Two reads carry the chart. First, diabetes blunts weight loss by roughly 6 to 7 percentage points versus non-diabetic obesity at the same dose, because long-standing high glucose dampens the metabolic cascade the drug works through.⁴ Second, the 10-to-15 mg step keeps adding weight loss in every band. That matters because blood-sugar control does the opposite: HbA1c is nearly maxed out by 10 mg, so the top dose is justified by weight, not by additional glucose lowering.⁵ ¹³

Body size also shifts the felt dose. Because the milligram amount is fixed, a lighter body gets more drug exposure per pound: roughly 22% more at 70 kg and about a third less at 120 kg, compared with a 90 kg reference.⁸ The dose still comes from response and tolerability, but a lighter person is running a hotter exposure at the same number on the vial.

Non-diabetic obese: the loudest instrument

This is the cleanest weight-loss setting and the right default anchor for obesity magnitude. In the SURMOUNT-1 body-composition substudy, run in that same roughly 105 kg cohort, about 75% of the weight lost is fat and 25% is lean, close to careful diet-and-exercise loss; tirzepatide takes off more total weight without changing that split, and visceral fat falls fastest, down about 40%.³ The benefit has to be held, though. In the withdrawal trial, when people stopped after reaching their loss, insulin resistance came back in proportion to the weight regained, so residual weight is not residual metabolic benefit.¹² Over-loss is uncommon here because the reserve is large, but it is real in deep responders who started at a lower BMI (more below).

Type 2 diabetes: sensitization, not just weight

Diabetes is a different instrument, not obesity with higher glucose, and its numbers travel only to a body that shares its baseline. Blood-sugar control is loud and saturates early. Across the diabetes trials HbA1c drops about 2.0 to 2.6 points and is close to its floor by 10 mg, while weight keeps responding to higher doses.⁵ ¹³ How far it falls depends on where it started: subgroups above 8% dropped past 3 points while subgroups under 8% dropped closer to 1.5 to 2, so a drug-naive trial average under-reads what a higher-baseline patient will see.¹³ The mechanism is the distinguishing one. Tirzepatide lowers glucose by making the body more insulin-sensitive rather than by forcing more insulin out, and in the insulin-background trials it replaced a large share of injected insulin, cutting basal insulin by roughly 60 to 80% while improving control.¹³ Low-blood-sugar risk tracks whatever insulin or sulfonylurea sits underneath it, not the tirzepatide dose.

Liver fat, visceral fat, and kidney markers move to the center here, and each still reads through its own baseline. Liver fat fell up to 47% at 15 mg in a fatty-liver diabetes substudy, a figure that only lands for someone who has liver fat to lose; a high-cardiovascular-risk kidney cohort showed a slower decline in kidney function and about a third less protein leak, which travels to a similar-risk body, not a healthy one.⁶ ¹⁴

Lean and metabolically healthy: a safety read, not an efficacy target

There is no long trial of tirzepatide in lean, metabolically healthy people, so this band is a translation, not a promise. Two things dominate. Exposure per milligram is higher, and may run above what body weight alone predicts in light, East-Asian users. And the reserve is lower, so the same 75/25 fat-to-lean split that is fine in obesity becomes a muscle concern sooner. The published cautionary case is a lean-adjacent, already-active man who lost about a third of his total weight as muscle on 2.5 mg alone, and only recovered it once he added resistance training and raised protein.¹⁶ The lever that defends muscle in a lean body is training and protein, not simply a lower dose. Heart rate is the other loud axis here, covered next.

Heart Rate: The Escalation Peak the Mean Hides

Tirzepatide's heart-rate effect is the most misread number on the drug, because the trials report two different things and people quote them interchangeably.

The short bars are the week-72 steady-state mean in the obese trial cohort, the calm number a maintenance patient settles into: about +0.6 to +2.6 bpm across the dose range.¹¹ The taller bars are the escalation peak, measured while the dose is still climbing around weeks 16 to 20, and it runs two to three times higher.¹¹ The two are different instruments. The chronic mean is not wrong; it just describes a different phase than the titration weeks a new user is living through.

The tail matters more than either average for the individual. Roughly 10% of people on tirzepatide have a jump of more than 20 bpm at some point during escalation, versus about 3% on placebo.¹¹ And the effect is phenotype-loaded: a lean Japanese cohort climbed to +10 to +13 bpm during escalation (the dashed band on the chart), and Japanese patients at 15 mg hit the abnormal-pulse threshold at 23% versus 7% in others, on only about 17% higher drug exposure.¹¹ The autonomic system in a lean or East-Asian body fires harder than exposure alone predicts. This is why resting heart rate is a weekly number to watch through the climb, not a box to check once. It is a titration-phase discomfort and a lean-tail concern, and it does not translate into worse long-term heart outcomes: the dedicated cardiovascular trial found no excess hard events and lower all-cause death.¹⁴

How to Titrate, and the Cost of Going Too Fast

The final dose decides the endpoint. Titration decides whether the body can stay on long enough to reach it. For tirzepatide the single biggest lever on side effects is not the destination dose. It is the speed of the climb.

The early program proved it directly. A fast two-week-step ramp to 15 mg pushed about a quarter of participants off the drug for side effects. Slowing the ramp to the label cadence (2.5 mg start, 2.5 mg steps, four-week holds) dropped that to mid-single digits at every maintenance dose, at no cost to the 12-week result, and the dedicated slow-titration trial reached placebo range.¹⁰ Reaching 15 mg is not the problem. Reaching it fast is.

The four-week hold is not arbitrary. Three clocks converge on it. Blood levels take about four weeks to settle after a step.⁸ The stomach-slowing effect that drives early nausea builds and then adapts over roughly the same window.⁹ And gut symptoms cluster at the first dose and at each increase, then ease with time on a held dose.¹⁰ The label waits for the last step to settle before adding the next.

That same stomach-slowing window is why oral birth control needs backup. After starting and after each dose increase, tirzepatide can cut the peak absorption of an oral contraceptive by more than half, so the label guidance is a non-oral method or added barrier protection for four weeks after starting and four weeks after each increase.⁹ ²² It is a first-dose-and-escalation effect, not a permanent block on all oral drugs.

Some phenotypes plausibly need a slower-than-label climb: lighter bodies (higher exposure per milligram), a history of severe GLP-1 gut intolerance, a high baseline heart rate, or a lean, low-reserve build. Slow titration lowers the acute burden; it cannot make a high dose appropriate for a low-substrate body, remove the heart-rate tail in a sensitive person, or guarantee anyone reaches 15 mg in real life.

Microdosing Tirzepatide

A tirzepatide microdose is best defined as below the 2.5 mg starter, usually 0.5, 1.0, 1.5, or 2.0 mg weekly. The 2.5 mg dose is better called the low-dose starter, because it is the labeled start and now has short direct non-diabetic data behind it.¹⁸

The use case is not rapid obesity-trial weight loss. It is lower-dose tolerability testing, metabolic-marker support, a cautious step-down after a full course, or maintenance translation for someone already stable. The evidence thins as the dose drops. The 1 mg dose has direct human activity from a 26-week diabetes dose-ranging trial, but its endpoint was blood sugar, not long-term weight.²¹ At 2.5 mg, a short outpatient cohort measured about -4.7% body weight over roughly four weeks along with better insulin-resistance markers.¹⁸ Below 1 mg is more speculative, resting on pharmacokinetics and mechanism.

Pen-based Mounjaro and Zepbound products do not dose below 2.5 mg. Sub-2.5 mg dosing depends on product format, clinician supervision, and current compounding rules. For vial-based microdosing, concentration matters more than vial size. A 10 mg vial in 2 mL of bacteriostatic water gives 5 mg/mL, where a 1 mg dose draws 0.2 mL (20 units on a U-100 syringe) and a 0.5 mg dose draws 0.1 mL (10 units). Smaller draws demand steadier technique.

Tirzepatide Maintenance Dose After Weight Loss

For most maintainers the practical band is 5-10 mg weekly, anchored by the obesity dose-response curve and real-world prescribing.¹ ¹⁸ The lower-dose track is 2.5 mg weekly, for someone stable for months who wants less drug exposure; that track has a short direct signal and real-world support, not long-duration proof.¹⁸

The strongest maintenance evidence is simple: continuing works far better than stopping. In the withdrawal trial, people who had been taken down to about 21% loss then kept taking tirzepatide held it, while those switched to placebo regained about 14% over the next year, and the continuers lost a further 5.5%.¹² Weight loss also does not continue forever on a held dose; it decelerates to a plateau, and that plateau is the biology defending a new set-point, not the drug quitting. Higher doses plateau later, so a plateau on 10 mg with the appetite still quiet may have more room at 15 mg.¹²

The step-down question is now answered. SURMOUNT-MAINTAIN held maintenance to week 112 at -21.9% on the continued top dose versus -16.6% stepping down to 5 mg versus -9.9% on placebo, with rescue therapy needed by 8%, 25%, and 67% respectively.¹² So 5 mg holds most of the loss against stopping, while continuing the effective dose holds more — a real reduced-dose option, not a full substitute.

Step down slowly, holding each step 8 to 12 weeks before deciding to reduce again. If hunger rises within 72 hours of the shot, waist drifts, weight climbs more than about 2 lb a month, resting heart rate stays elevated, or strength drops despite protein and training, the lower dose is not carrying the load.

Coming Off Tirzepatide

Stopping brings appetite and weight-regain pressure back, and that regain is the default, not a willpower failure. It is class-wide counter-regulation: stopping removes the signal that was holding down a set-point the body still defends.¹² The felt marker of the rebound is the return of food noise, which patients in the exit interviews reported as the first sign the loss was reversing.¹²

Two facts make the landing the part to protect. The metabolic give-back tracks the regain: hold most of the weight off and insulin sensitivity holds, but in that same withdrawal cohort, regaining half of it sent insulin resistance up roughly 35 to 40%.¹² And blood pressure re-pressurizes as weight returns.¹² So a taper, not a hard stop, plus protein at roughly 0.7 g per pound and resistance training from the start, is the framework that gives eating and training patterns time to consolidate before the drug signal fades. The tracked evidence does not yet cover restart kinetics cleanly, so how fast a returning user should re-titrate is genuinely unsettled.

Side Effects and Safety

Read the profile through four buckets and most misreadings disappear. Gut, heart rate, and stomach-emptying effects are dose- and titration-coupled, driven more by escalation speed than final dose. Low blood sugar is set by the insulin or sulfonylurea underneath, not by tirzepatide. The class-level concerns (pancreatitis, gallbladder, thyroid, kidney) sit at low single digits with no tirzepatide-specific signal. And a few "adverse events" in the tables are net benefits mislabeled by the dictionary.

One frame sits over all four. A trial's adverse-event table is itself an instrument. It counts what passive reporting in a clinic logged, which runs below what users report unprompted in the real world, and it can only count what it thought to ask about, so a real effect the trial never pre-specified is absent from the table without being absent from users. The rates below are that instrument's reading; where a symptom is common in the wild but quiet in the tables, that gap is usually the instrument, not the drug.

Gastrointestinal effects: the main titration bottleneck

Nausea, diarrhea, constipation, and vomiting run around 40 to 44% overall, dose-dependent in how many people report them but mild-dominant in severity: severe events stay at or below about 1.7% in any category even at the top dose.⁸ In the obesity program the by-dose rates run nausea 25/29/28%, diarrhea 19/21/23%, and vomiting 8/11/13% at 5/10/15 mg.⁸ They concentrate during escalation and ease with time on a held dose.

Heart rate: the escalation transient

This is the two-instruments effect covered above: a modest chronic mean, a larger escalation peak, and a lean, East-Asian tail.¹¹ Blood pressure moves the other way, down about 6 to 9 mmHg systolic, so the heart-rate rise is not a blood-pressure effect, and it reverses when the drug stops.²⁰

Low blood sugar tracks the insulin background

On its own tirzepatide is insulin-sparing and rarely causes low blood sugar. Stacked on top of insulin or a sulfonylurea it can, and the lever is de-intensifying that background drug, not lowering the tirzepatide dose.¹³

Over-loss in low-BMI deep responders

Pooled across the obesity trials, about 7% of people dropped below a BMI of 22 (some as early as week 12), rising toward 15% by week 88 in the longest trial, while clinical underweight stayed rare at under half a percent.¹⁶ The signal lands on the low-baseline deep responder, and the move there is a hold or step-down rather than a blanket ceiling. One caveat the trials cannot answer: micronutrient status was never systematically measured, so "nutrition events were uncommon" is bounded by what the trials looked for.

Skin sensitivity: an emerging signal

Skin burning and abnormal touch sensitivity (dysesthesia) is the clearest case of that instrument gap. It is an emerging, dose-related, reversible signal, documented in two published case series and flagged in pharmacovigilance, and reported for the GLP-1 class as a whole, but the trials never pre-specified it, so it lives in case reports and post-market data rather than the AE tables.¹⁹ It is not on the tirzepatide label, tirzepatide's share of these nerve reports is lower than semaglutide's, and no incidence has been established. Flag it if it appears at higher doses; it eases when the dose comes down. Do not assume a rate.

Class-level and rare concerns

Pancreatitis runs about 0.2% and is not dose-related. Gallbladder disease rises with faster, larger weight loss. A rodent-based thyroid boxed warning carries no human signal at trial resolution, with a personal or family history of medullary thyroid cancer or MEN2 as a contraindication. Kidney injury appears only as a secondary effect of dehydration from severe gut upset.⁸ ¹⁴ Anti-drug antibodies form in roughly half to two-thirds of users but do not affect clearance, weight, or blood sugar.²²

Benefits that look like side effects

Tirzepatide lowers uric acid (about -0.7 to -1.0 mg/dL, mostly through weight loss) and lowers blood pressure. Both appear in adverse-event tables as preferred terms, but they are benefits, not harms.²⁰

Split Dosing and Frequency

The trial and label schedule is once weekly. Splitting the same weekly total into two injections, often every 3 to 4 days, is a tolerability strategy used outside the formal schedule. A smaller per-injection peak may reduce nausea and heart-rate pressure during escalation, and a smaller trough may soften the late-week hunger some users report. The evidence is pharmacokinetic and practice-based, not controlled outcome evidence.

Extended intervals are the weakest layer. With a roughly 5-day half-life, a biweekly schedule creates a real valley before the next shot. If hunger, waist, or weight drift shows up in the back half of the interval, weekly dosing is the cleaner maintenance schedule.

Compounded Tirzepatide Dosage

Branded Mounjaro and Zepbound pens are fixed-dose products. A 5 mg pen delivers 5 mg. It does not create a 1 mg microdose, a 2 mg split, or a custom intermediate step. Vial-based dosing is where concentration and syringe-unit math matter.

Product access and compounding rules change. Do not assume a specific format is currently legal, available, or clinically appropriate. If vial-based tirzepatide is being used under clinician supervision, verify the source, concentration, sterility expectations, and current rules before doing dose math. The calculator answers only the arithmetic: how many milliliters and U-100 units match a target milligram dose.

The core formula is:

Volume to draw (mL) = desired dose (mg) / concentration (mg/mL)

Concentration comes from the vial and BAC water:

Concentration (mg/mL) = total vial amount (mg) / BAC water added (mL)

The per-vial BAC water and syringe-unit charts for the 10, 15, 20, 30, and 60 mg vials are in the How to Reconstitute Tirzepatide section below; the full mixing walkthrough lives on the reconstitution calculator. The total milligrams in the vial are fixed; BAC water only changes concentration and draw volume.

How to Reconstitute Tirzepatide

How FoxAI Calculates Your Tirzepatide Dose

The FoxAI calculator uses vial size, BAC water volume, weekly target dose, and frequency to return concentration, draw volume, and U-100 syringe units. It handles label doses, lower-dose maintenance, microdose values, and split schedules. The calculation is arithmetic. The dose decision needs context the calculator cannot supply: population, phenotype, dose history, resting heart rate, oral-medication timing, and what the markers are doing.

FAQ

Related Topics

• Tirzepatide Deep Dive — mechanism, clinical results, and comparison context
• Retatrutide vs Tirzepatide — triple versus dual receptor comparison
• Semaglutide vs Tirzepatide — direct comparison and evidence boundaries
• GLP-1 Dosing Optimizer — split-frequency modeling and plasma curves
• Full Reconstitution Calculator — all-peptide vial math and custom BAC volumes
• GLP-1 Lean Mass Guide — protein, training, and body-composition evidence

References

¹ Tirzepatide for non-diabetic obesity — SURMOUNT-1, 72 weeks, 5/10/15 mg, weight -15.0/-19.5/-20.9% (treatment-regimen estimand), DXA and pulse in Table S7: Jastreboff NEJM 2022.

² Tirzepatide vs semaglutide 2.4 mg in non-diabetic obesity — SURMOUNT-5 direct head-to-head, -20.2% vs -13.7% at 72 weeks: Aronne NEJM 2025.

³ Tirzepatide body-composition DXA substudy — pooled SURMOUNT-1, about 75:25 fat-to-lean loss, visceral fat about -40%: Look DOM 2024.

⁴ Tirzepatide for T2D obesity — SURMOUNT-2, weight -12.8/-14.7% at 10/15 mg, attenuated about 6-7 points vs non-diabetic obesity: Garvey Lancet 2023.

⁵ Tirzepatide vs semaglutide 1 mg in T2D — SURPASS-2, HbA1c -2.01/-2.24/-2.30 pp, weight dose-responsive while HbA1c saturates: Frias NEJM 2021.

⁶ Tirzepatide liver-fat and body-composition MRI substudy — SURPASS-3, relative liver-fat reduction -29.8/-39.6/-47.1% at 5/10/15 mg vs insulin degludec -11.2%: Gastaldelli Lancet D&E 2022.

⁷ Tirzepatide receptor pharmacology and predicted receptor occupancy — GIPR-forward dual-incretin design, cAMP-biased GLP-1R with low beta-arrestin, GCGR negative control (EC50 329 nM); free-drug occupancy method (albumin Kd 1.86 uM, free fraction 0.29%): Willard JCI Insight 2020; Coskun Mol Metab 2018.

⁸ Tirzepatide population pharmacokinetics and exposure — Schneck 19-study pooled popPK (CL/F 0.061 L/h, half-life 5.4 d, accumulation 1.7x, body-weight covariate +22% at 70 kg / -33% at 120 kg); MHRA-measured Phase-3 Cav,ss 491/1470 ng/mL at 5/15 mg; pooled safety database: Schneck CPT:PSP 2024; FDA Mounjaro NDA 215866 / Zepbound NDA 217806 reviews.

⁹ Tirzepatide gastric emptying and the oral-drug interaction — GLP-1R-mediated delay at 4.5-5 mg, tachyphylaxis by about 4 weeks, re-engagement on escalation; ethinyl estradiol Cmax -59%, norgestimate -55%: Urva DOM 2020.

¹⁰ Titration governs tolerability — fast 2-week ramp to 15 mg gave 24.5% AE-discontinuation (Frias 2018); slow 8-week regimens brought it to 0-3.8%, near placebo, at no efficacy cost (Frias 2020): Frias Lancet 2018; Frias DOM 2020.

¹¹ Heart-rate escalation peak vs steady-state mean — SURMOUNT-1 week-72 pulse +0.6/+2.3/+2.6 bpm; FDA Zepbound Medical Review (Soccio) escalation peak at weeks 16-20 +2.8/+5.1/+4.1 bpm, change over 20 bpm in about 10% of tirz vs 3.35% placebo, Japanese 15 mg abnormal-pulse 23.3% vs 7.1%; Furihata lean Japanese Phase 1 +10 to +13 bpm during escalation: FDA Zepbound NDA 217806 Medical Review; Furihata DOM 2022.

¹² Maintenance and discontinuation — SURMOUNT-4, continue vs placebo switch after lead-in to about 20.9% loss: stopping regained about +14% over 52 weeks while continuing lost a further -5.5%; HOMA2-IR returns in proportion to regain (about +0.6% at under-25% regain to +39.5% at 50-75%); time-to-plateau lengthens with dose. SURMOUNT-MAINTAIN (Horn 2026, 112 weeks): continued top dose -21.9% vs 5 mg step-down -16.6% vs placebo -9.9%, rescue therapy 8/25/67%: Aronne JAMA 2024; Horn Lancet 2026; NCT06047548.

¹³ Glycemic mechanism and insulin sparing — sensitization not secretion: fasting insulin and C-peptide fall while insulin sensitivity (HOMA2-%S) rises +31.8/+43.2/+49.9% (SURPASS J-mono, Hamamoto 2025); basal insulin cut from 47 to 8-20 IU replacing basal-bolus (SURPASS-6); hypoglycemia tracks the insulin background not tirzepatide dose (SURPASS-5): Dahl JAMA 2022; Rosenstock JAMA 2023; Hamamoto Diabetes Ther 2025.

¹⁴ Kidney and cardiovascular outcomes — SURPASS-4 kidney composite HR 0.58, slower eGFR decline (-1.4 vs -3.6 mL/min/1.73m2/yr), UACR -6.8% vs +36.9%; SURPASS-CVOT (N=13,165) noninferior on 3-point MACE (HR 0.92), significant on 4-point MACE (0.88) and all-cause death (0.84): Heerspink SURPASS-4 kidney post-hoc; Nicholls NEJM 2025.

¹⁵ Tirzepatide for MASH with fibrosis — 15 mg produced a large majority disease-resolution rate versus a small placebo rate: Loomba NEJM 2024 (SYNERGY-NASH).

¹⁶ Over-loss and muscle — pooled SURMOUNT, BMI below 22 reached by about 7% (as early as week 12), toward about 15% by week 88 in the longest trial, clinical underweight under 0.4% (Almandoz 2026); muscle volume falls as weight predicts while muscle quality improves beyond estimate (Sattar 2025 muscle); lean-adjacent n=1 case lost about a third of weight as muscle on 2.5 mg, recovered with resistance work and protein: Almandoz Obes Pillars 2026; Sattar Lancet D&E 2025.

¹⁷ Appetite and food reward — 3-arm Phase 1 tirzepatide vs liraglutide 3.0 mg vs placebo: measured lunch intake fell 524.6 kcal vs placebo by week 3 (about 72% by week 6), with craving and hedonic-hunger reductions exceeding liraglutide; drive to eat, not willpower: Martin Nat Med 2025.

¹⁸ Real-world dosing and outcomes — 6-month persister loss about 12-13% (Hankosky), broad-cohort about -9.8% (Adamidis), telehealth completers near -23% (Duncan); modal maximum dose often 5 mg with many below 10 mg by the sixth fill (Mody); tirzepatide out-loses semaglutide even at lower dose intensity (le Roux); short 2.5 mg cohort about -4.7% at ~4 weeks, -12.7% by the 5 mg phase (Barrea 2026): Mody Diabetes Ther 2025; Hankosky DOM 2025; le Roux J Endocrinol Invest 2026; Duncan Obes Pillars 2026; Barrea EXCLI J 2026;25:191-203.

¹⁹ Cutaneous dysesthesia / allodynia — emerging, dose-related, reversible; two published tirzepatide case series (Naranjo "probable"), FAERS reporting odds ratio 22.55 for allodynia across GLP-1 with tirzepatide's neuro-AE proportion lower than semaglutide's, class cohort signal (aHR 2.15) in related agents; not on the tirzepatide label, incidence unknown: Ahern Cureus 2025; Chakrabarti/Campbell Am J Case Rep 2026; Chen Sci Rep 2025;15:18063; Frey medRxiv 2026 (preprint).

²⁰ Net-beneficial preferred terms — uric acid lowered -0.69/-0.92/-0.95 mg/dL (about 73% mediated by weight loss); systolic blood pressure down 6-9 mmHg, reversing on withdrawal: Sattar Ann Rheum Dis 2026.

²¹ Phase 2 tirzepatide dose-ranging in T2D — 1, 5, 10, and 15 mg over 26 weeks; the 1 mg arm is the lowest measured human pharmacologic activity: Frias Lancet 2018.

²² Oral-contraceptive interaction and immunogenicity — backup or non-oral contraception for 4 weeks after initiation and each escalation; anti-drug antibodies in about 51% (diabetes) to 64.5% (obesity) of users with no effect on clearance, weight, or HbA1c: FDA Mounjaro NDA 215866 label and Summary Review; FDA Zepbound NDA 217806 Summary Review.

²³ Real-world patient-language layer — recurring themes and vocabulary drawn from the tirzepatide Reddit communities (r/Zepbound, r/Mounjaro, r/tirzepatide and related), read for theme prominence and the words users use, not for incidence. Among users who post about side effects, the most-discussed run nausea, fatigue, GI-other, anxiety, diarrhea, constipation, menstrual changes, and reflux/burps, in that order; "food noise" is the near-universal term for the appetite change. This is a signal-discovery instrument: proportions are among side-effect-disclosing posters rather than population rates, and symptom posts are structurally under-represented against progress posts, so it supports vocabulary and theme prominence, not magnitude. PeptideFox tirzepatide real-world evidence corpus.